Jefferies Downgrades uniQure BV (QURE) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Jefferies Downgrades uniQure BV (QURE) to Hold
November 22, 2016 7:06 AM EST
~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its financial results for the third quarter ended September 30, 2016 and provided an update on corporate developments.
"With the completion of our company-wide strategic review, we have focused our pipeline, streamlined  operations... More
November 22, 2016 7:00 AM EST
~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its financial results for the third quarter ended September 30, 2016 and provided an update on corporate developments.
With the completion of our company-wide strategic review, we have focused our pipeline, streamlined... More
